SPY305.55+1.23 0.40%
DIA255.27+0.98 0.39%
IXIC9,552.05+62.18 0.66%

Recap: Assertio Therapeutics Q1 Earnings

Shares of Assertio Therapeutics (NASDAQ:ASRT) rose 9% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 56.52% over the past year to $0.10, which beat the estimate of ($0.08).

Benzinga · 05/11/2020 12:17

Shares of Assertio Therapeutics (NASDAQ:ASRT) rose 9% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 56.52% over the past year to $0.10, which beat the estimate of ($0.08).

Revenue of $20,917,000 less by 63.89% from the same period last year, which beat the estimate of $11,300,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 11, 2020

Time: 08:01 PM ET

Webcast URL: https://edge.media-server.com/mmc/p/vryis85c

Technicals

52-week high: $4.92

Company's 52-week low was at $0.55

Price action over last quarter: Up 10.80%

Company Description

Assertio Therapeutics Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.